JP2015523346A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523346A5
JP2015523346A5 JP2015516261A JP2015516261A JP2015523346A5 JP 2015523346 A5 JP2015523346 A5 JP 2015523346A5 JP 2015516261 A JP2015516261 A JP 2015516261A JP 2015516261 A JP2015516261 A JP 2015516261A JP 2015523346 A5 JP2015523346 A5 JP 2015523346A5
Authority
JP
Japan
Prior art keywords
day
neutropenia
retinoid agonist
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516261A
Other languages
English (en)
Japanese (ja)
Other versions
JP6295249B2 (ja
JP2015523346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044828 external-priority patent/WO2013185105A1/en
Publication of JP2015523346A publication Critical patent/JP2015523346A/ja
Publication of JP2015523346A5 publication Critical patent/JP2015523346A5/ja
Application granted granted Critical
Publication of JP6295249B2 publication Critical patent/JP6295249B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516261A 2012-06-07 2013-06-07 レチノイドアゴニストを用いた好中球減少症の治療方法 Expired - Fee Related JP6295249B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US61/656,815 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (3)

Publication Number Publication Date
JP2015523346A JP2015523346A (ja) 2015-08-13
JP2015523346A5 true JP2015523346A5 (enExample) 2016-06-16
JP6295249B2 JP6295249B2 (ja) 2018-03-14

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516261A Expired - Fee Related JP6295249B2 (ja) 2012-06-07 2013-06-07 レチノイドアゴニストを用いた好中球減少症の治療方法

Country Status (13)

Country Link
US (1) US11116738B2 (enExample)
EP (1) EP2858636B1 (enExample)
JP (1) JP6295249B2 (enExample)
KR (1) KR102083046B1 (enExample)
CN (1) CN104519879B (enExample)
AU (1) AU2013270674B2 (enExample)
BR (1) BR112014030279A2 (enExample)
CA (1) CA2874850A1 (enExample)
ES (1) ES2691493T3 (enExample)
MX (1) MX365321B (enExample)
NZ (1) NZ702415A (enExample)
RU (1) RU2650962C2 (enExample)
WO (1) WO2013185105A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874850A1 (en) 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
WO2014145295A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing aging effects
CN106413701A (zh) * 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法
EP3277272B1 (en) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
US20210123021A1 (en) * 2018-01-26 2021-04-29 Agency For Science, Technology And Research Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
WO1998026781A1 (en) * 1996-12-19 1998-06-25 American Cyanamid Company Method of treating or inhibiting neutropenia
CA2421760A1 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004100972A1 (ja) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
BRPI0514343A (pt) 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
PL1841432T3 (pl) 2004-12-02 2011-01-31 Venus Remedies Ltd H O&R&D Kompozycje do zwalczania oporności antybiotykowej opartej na aktywności beta-laktamazy przy użyciu inhibitorów beta-laktamazy przeznaczonych do iniekcji
US20090111786A1 (en) 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
JP2009537540A (ja) * 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
JP5539713B2 (ja) * 2007-03-30 2014-07-02 テムリック株式会社 タミバロテンカプセル剤
BRPI0819887A2 (pt) * 2007-12-06 2017-05-23 Csl Ltd métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno
EP2334814A4 (en) 2008-09-05 2012-04-25 Solulink Biosciences Inc METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA INJURIES
AU2010309388B2 (en) 2009-10-19 2016-03-10 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
AU2013259624B2 (en) * 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CA2874850A1 (en) 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN106413701A (zh) 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法

Similar Documents

Publication Publication Date Title
JP2015523346A5 (enExample)
JP2013533858A5 (enExample)
JP2019519519A5 (enExample)
JP2016535786A5 (enExample)
JP2014510729A5 (enExample)
JP2015529225A5 (enExample)
JP2012046518A5 (enExample)
JP2017512193A5 (enExample)
JP2014074046A5 (enExample)
JP2012121878A5 (enExample)
RU2014153988A (ru) Способы лечения нейтропении с применением ретиноидных агонистов
JP2009298801A5 (enExample)
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
JP2009544279A5 (enExample)
JP2012144574A5 (enExample)
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
MX2009006066A (es) Tratamiento de cerdos con el antigeno pcv.
JP2011157378A5 (enExample)
JP2012522010A5 (enExample)
JP2018505882A5 (enExample)
JP2016516074A5 (enExample)
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
JP2017530130A5 (enExample)
JP2015511625A5 (enExample)
JP2008154589A5 (enExample)